Showing results (351-360 of 357) with videos related to
Sort By:
Pageof 36
You have reached the last page of results.This site can display upto 357 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2000
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomasI Cokgor, G Akabani, C T Kuan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial resultsD D Bigner, M T Brown, A H Friedman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiationP R Thomas, M Deutsch, J L Kepner, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 1996
Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial resultsM T Brown, R E Coleman, A H Friedman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant gliomaH S Friedman, R E McLendon, T Kerby, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Irinotecan therapy in adults with recurrent or progressive malignant gliomaH S Friedman, W P Petros, A H Friedman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant gliomaH S Friedman, J Pluda, J A Quinn, et al.Pageof 36